Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_5705_Библиотеки_им_академика_М_И_Перельмана.pdf
X
- •About the Editor
- •Contents
- •Contributors
- •1.1.4 Components of niosome
- •1.1.5 Factors affecting niosomes
- •Preface
- •Abstract
- •1.1 Introduction
- •1.1.1 Why niosome?
- •1.1.2 Advantages of niosome
- •1.1.3 Structure of niosome
- •1.2 Applications of niosome
- •1.2.2 Niosomes for the delivery of therapeutics
- •1.2.3 Niosomes in biomedical applications
- •1.3 Conclusions and future prospects
- •Keywords
- •References
- •Abstract
- •2.1 Introduction
- •2.2 Conclusions
- •Acknowledgments
- •Keywords
- •References
- •Abstract
- •3.1 Introduction
- •3.2.1 Parameters involved in electrospinning process
- •3.2.2 Biomaterials for electrospinning
- •3.3 Electrospun nanofibers as drug delivery systems
- •3.3.1 Blending electrospinning
- •3.3.2 Emulsion electrospinning
- •3.3.3 Coaxial electrospinning
- •3.3.4 Surface modifications
- •3.4 Electrospun nanofibers for tissue engineering
- •3.4.1 Electrospun nanofibers for hard tissue engineering
- •3.5 Cancer diagnosis and therapy
- •3.6 Concluding remarks and future perspectives
- •Keywords
- •References
- •4. Natural Biocarriers for Brain Targeting
- •Abstract
- •4.1 Introduction
- •4.1.1 Central nervous system
- •4.2 Biocarriers
- •4.2.1 Carbohydrates carriers
- •4.2.2 Protein carriers
- •4.2.3 Exosomes
- •4.3 Conclusions and perspectives
- •Keywords
- •References
- •Abstract
- •5.1 Introduction
- •5.2 Synthesis of graphene family nanomaterials
- •5.2.1 Graphene synthesis
- •5.2.2 GO and rGO Syntheses
- •5.2.3 GQd synthesis
- •5.4 Drug delivery and biomedical applications
- •5.4.1 Drug delivery
- •5.4.2 Gene delivery
- •5.4.3 Bioimaging
- •5.4.4 Photothermal therapy
- •5.4.5 Tissue engineering
- •5.5 Summary and future prospect
- •Keywords
- •References
- •6. Nanotechnology in Gene Delivery
- •Abstract
- •6.1 Introduction
- •6.2 Gene delivery
- •6.3 Nanotechnology in gene delivery
- •Keywords
- •References
- •Abstract
- •7.1 Introduction
- •7.2 Additive manufacturing in pharmacology
- •7.2.1 Extrusion-based 3D printing techniques
- •7.2.2 Stereolithography
- •7.2.3 Selective laser sintering
- •7.2.4 Binder jet printing
- •7.3 Most common polymers
- •7.3.1 Natural polymers
- •7.3.2 Synthetic polymers
- •7.3.2.5 Polyvinylpyrrolidone
- •7.4 Common 3D-printed dosage forms
- •7.4.1 Scaffolds
- •7.4.2 Tablets
- •Keywords
- •References
- •7.4.3 Microneedles
- •7.4.4 Capsule
- •7.4.5 Films
- •7.5 Main factors in drug delivery
- •7.5.1 Nature of polymers
- •7.5.2 Matrix permeability
- •7.5.3 Polymer blends
- •7.5.4 Specific surface area
- •7.5.5 Infill density and patterns
- •7.5.6 Pores
- •7.5.7 Cross-linking
- •7.5.8 Coating
- •7.5.9 Core/shell and multicompartment
- •7.6 Final considerations and future perspectives
- •Abstract
- •8.1 Introduction
- •8.2.1 Polymer solution concentration and viscosity
- •8.2.2 Molecular weight of polymer
- •8.2.3 Surface tension
- •8.2.4 Electrical conductivity
- •8.2.5 Applied voltage
- •8.2.6 Feed rate/flow rate
- •8.2.7 Temperature and humidity
- •8.3 Method of preparation for nanofibers
- •8.3.1 Electrospinning
- •8.3.2 Self-assembly
- •8.3.3 Phase separation
- •8.3.4 Drawing of nanofibers
- •8.3.5 Template synthesis
- •8.4 Biomedical applications of nanofibers
- •8.4.1 Wound dressing
- •8.4.2 Tissue engineering
- •8.4.3 In cancer therapy
- •8.4.4 Miscellaneous
- •8.5 Drug delivery application
- •8.5.1 Antihypertensive drug
- •8.5.2 Antimicrobial drug
- •8.5.3 Growth hormone
- •8.5.4 Miscellaneous
- •8.6 Conclusion
- •Keywords
- •References
- •Abstract
- •9.1 Introduction
- •9.2 Tissue engineering
- •9.3 Nanotechnology
- •9.4 Polymeric scaffolds in tissue engineering
- •9.5 Challenges
- •Keywords
- •References
- •Abstract
- •10.1 Introduction
- •10.2 Ideal properties of bioceramics
- •10.2.1 Mechanical property
- •10.2.2 Porosity, pore size, and shape
- •10.2.3 Biocompatibility and biodegradability
- •10.2.4 Osteoconductivity and osseointegrity
- •10.3 Bioceramics in orthopedic applications
- •10.4 Bioceramics in maxillofacial surgery
- •10.5 Bioceramic in drug delivery applications
- •10.6 Doped bioceramic in biomedical application
- •10.7 Conclusions
- •10.8 Future direction
- •Acknowledgments
- •Keywords
- •References
- •Index

258
Advances in Pharmaceutical Technology for Drug Delivery Systems (PTDDS), Volume 2
Xu et al., 2008).
-
-
organs and is able to achieve the required drug concentration around the
produce comparatively better cell death percentage and tumor inhibition rate
8.4.4 MISCELLANEOUS

Nanofiber Technology in Biomedical Applications
259
-
-
-
-
-
al., 2006).
8.5 DRUG DELIVERY APPLICATION

260
Advances in Pharmaceutical Technology for Drug Delivery Systems (PTDDS), Volume 2
TABLE 8.2 Drug Delivery Application.
Drug classification System name Drug used Polymer used References
Antihypertensive drug
Valsartan Polyvinylpyrrolidone
K-90 (PVP K-90)
2021
Irbesartan PVP K-90 Adeli, 2015
Biodegradable composite
Captopril and
Poly(l-lactic acid) (PLLA) Wei et al., 2011
PVP K-90 and l-arginine
2021
Antimicrobial drug PVA and poly(ethylene
oxide)
2012
Pullulan
PCL Monteiro et al., 2017
PVA, CS, and hyaluronic
acid
Hosseini et al., 2021
Buccal adhesive double-
hGH Eudragit and CS Choi et al., 2016
Miscellaneous Curcumin and
Almond gum and PVA
2019
Resveratrol CS and gellan Rostami et al., 2019
CS Behbood et al., 2018
Indomethacin Eudragit S and Eudragit
RS
Akhgari et al., 2017

Nanofiber Technology in Biomedical Applications
261
8.5.1 ANTIHYPERTENSIVE DRUG
-
-
-

262
Advances in Pharmaceutical Technology for Drug Delivery Systems (PTDDS), Volume 2
drugs. So, all the results conclude that the compound antihypertensive drugs
8.5.2 ANTIMICROBIAL DRUG
to exhibit antimicrobial activity against the Escherichia coli, P. aeruginosa,
Aspergillus niger, Penicillium notatum, and Aspergillus flavus. So, this
antimicrobial agent by the electrospinning technology using pullulan
(21–25)
Pal
E. coli

Nanofiber Technology in Biomedical Applications
263
-
Aggre-
gatibacter actinomycetemcomitans and Porphyromonas gingivalis and they
delivery (Monteiro et al., 2017).
8.5.3 GROWTH HORMONE
and hyaluronic acid polymers due to their biodegradability , biocompatibility ,
-
hormones (Hosseini et al., 2021).
-

264
Advances in Pharmaceutical Technology for Drug Delivery Systems (PTDDS), Volume 2
materials (Choi et al., 2016).
8.5.4 MISCELLANEOUS
R
2
value greater than 0.9176. So, it
and Nasirpour, 2019).
-
-

Nanofiber Technology in Biomedical Applications
265
-
8.6 CONCLUSION
-
tissue regeneration. Recently, several studies have reported its applications
KEYWORDS
• nanofiber
• electrospun
• drug delivery
• biopolymer
• wound healing

266
Advances in Pharmaceutical Technology for Drug Delivery Systems (PTDDS), Volume 2
REFERENCES
Jundishapur J. Microbiol. 2015, 8 (10).
J.
Appl. Polym. Sci. 2015, 132 (27).
Evaluation and in Vitro Healing Assay. Int. J. Biol. Macromol. 2019, 122, 238–254.
Dissolution Studies. Colloids Surfaces B: Biointerfaces 2017, 152, 29–35.
Biomedical Applications. Nanomaterials 2018, 8 (4), 259.
J. Text. Assoc. 2017,
78 (1), 5–14.
1934.
Biochemistry (Moscow) 2003, 68 (11), 1261–1266.
Proceedings of the 3rd International Conference
on Nanotechnology-Smart Materials (NANOCON’11)2011.
Filtering Media. J. Membr. Sci. 2006, 283 (1–2), 209–218.
Delivery System. Fibers Polym. 2018, 19 (7), 1454–1462.
Adv. Mater. 1999, 11 (16), 1362–1365.
Biotechnol. Adv . 2010, 28 (3), 325–347.
Pharmaceutics 2018, 11 (1), 5.
Pharm. Dev. Technol. 2021, 26 (6), 661–672.
J. Pharm. Sci. 2008, 97 (8), 2892–2923.
Adv. Mater. 2001,
13 (1), 70–72.
Nature 2003, 424 (6950), 805–808.

Nanofiber Technology in Biomedical Applications
267
J. Biomed. Mater. Res. Part B: Appl. Biomater . 2016,
104 (7), 1396–1406.
Polymer 2001, 42 (1), 261–272.
Polymer 2002, 43 (11), 3303–3309.
Nanoscale 2014, 6 (16), 9477–9493.
Death. Int. J. Biol. Macromol. 2020, 164, 1461–1474.
and Biomedical Applications. Artif. Cells Nanomed. Biotechnol. 2016, 44 (1), 111–121.
Fibers Polym. 2012, 13 (6), 709–717.
J. Cell Biol. 1972, 54
(3), 626–637.
Nanofibers-
Prod. Propert. Funct. Appl. 2011, 14, 287–302.
Chem. Rev.
2005, 105 (4), 1171–1196.
Engineering. Int. J. Biol. Macromol. 2017, 102, 1174–1185.
Sci. Am. 2002, 3.
Polym. Adv .
Technol. 2018, 29 (12), 2972–2981.
Phys. Status Solidi
(a). 2007, 204 (6), 1830–1834.
Biotechnology. Arabian J. Chem. 2018, 11 (8), 1165–1188.
PNAS 2002, 99 (8), 5133–5138.
Investigations. Polym. Adv . Technol. 2021, 32 (2), 574–581.
a PLLA–Dioxane–Water System. J. Biomed. Mater. Res.: Off. J. Soc. Biomater. Jpn. Soc.
Biomater. Austr. Soc. Biomater. Korean Soc. Biomater. 2002, 63 (2), 161–167.
Соседние файлы в папке Библиотека им академика М.И. Перельмана
